Prepared Highlights
- 总收入同比增长39%至2.652亿美元，肿瘤、生物制药和筛查业务均实现增长 (prepared)
- 肿瘤业务收入同比增长31%至1.844亿美元，检测量同比增长40%至约74,000次 (CEO)
- 生物制药与数据业务收入同比增长18%至5,470万美元 (CFO)
- 筛查业务Shield收入2,410万美元，检测量24,000次，ASP约880美元 (CFO)
- 非GAAP毛利率升至66%，Shield非GAAP毛利率达55% (CFO)
- 剔除筛查业务后，核心业务实现自由现金流正贡献，比预期提前一个季度 (CFO)
- 自由现金流消耗4,580万美元，同比改善950万美元 (CFO)
- 期末现金及等价物约6.9亿美元 (CFO)
- 累计临床患者突破100万例 (CEO)
- 官方指引：2025全年收入9.65亿至9.7亿美元，同比增长约31% (CFO)
- 官方指引：2025全年肿瘤收入同比增长约25%，Shield收入7,100万至7,300万美元（检测量8万至8.2万次） (CFO)
- 官方指引：2025全年非GAAP毛利率64%至65%，运营费用8.65亿至8.75亿美元，自由现金流消耗2.25亿至2.35亿美元 (CFO)
Prepared Metrics (table if ≥3 numeric items)
| Metric | Value | Speaker/Context |
| 肿瘤检测量 | 74,000次（+40% YoY） | (CEO) |
| Shield ASP | 约880美元 | (CFO) |
| 非GAAP毛利率 | 66% | (CFO) |
| 2025全年收入指引 | 9.65亿–9.7亿美元 | (CFO) |
| 2025全年FCF消耗指引 | 2.25亿–2.35亿美元 | (CFO) |
- “Q3是Guardant表现优异的一个季度，业务实现广泛增长。” (CEO)
- “我们首次跨越10亿美元年化收入里程碑。” (CEO)
- “Shield筛查已形成约1亿美元年化收入规模。” (CEO)
- “核心业务已提前实现自由现金流正贡献。” (CFO)
- “我们持续降低筛查业务成本并提升毛利率。” (CFO)
Q&A Batch (1-5 of 13)
Q1 — Bradley Bowers
- Topic: Shield ASP dynamics and phasing to 2028
- Key points:
- Shield ASP exiting the year at $900, expected to decline to $700 by 2028.
- Medicare ADLT rate is $1,495, effective Q2; Medicare Advantage payers also paying at $1,495 rate; majority of volume skewed to Medicare/Medicare Advantage.
- Commercial patients currently paying effectively $0; future ASP fluctuation driven by commercial mix and ramp-up of commercial reimbursement.
- Company submitted pricing package to Medicare for the last six months, expects to maintain $1,495 rate for at least the next 2 years.
- Mgmt stance: Bullish — management is “really happy” with current ASP and confident in $1,495 rate, with Medicare Advantage potentially strengthening further.
Q2 — Douglas Schenkel
- Topic: ACS guideline inclusion and commercial coverage timeline
- Key points:
- ACS research team appears “almost done” with their work; company remains confident about potential Shield inclusion in near future.
- Guideline inclusion is not part of the current year’s guide; no upside counted on.
- Initial impact would be on appeal success rate, then product coverage and contracting successes.
- Florida now provides Medicaid access to Shield; broader universe of states (e.g., Florida, Louisiana) could bring coverage closer to 20% over the next year.
- Mgmt stance: Neutral — optimistic about ACS guideline potential but explicitly not counting on any upside in current guidance; monitoring closely.
Q3 — Puneet Souda
- Topic: Shield 2026 growth and Guardant360 (G360) performance
- Key points:
- Shield growth accelerating on volumes and ASP; company consistently raised outlook throughout 2025.
- Too early to comment on 2026 Shield growth; long-term outlook from Investor Day remains unchanged.
- G360 launched 11 years ago, still growing 30%+; attributed to platform expansion with Smart apps and increasing clinical utility.
- Liquid biopsy is described as “very, very early innings” in oncology; trajectory expected to continue over the next decade.
- Mgmt stance: Bullish — pleased with Shield momentum and G360 performance; confident in long-term outlooks.
Q4 — Subhalaxmi Nambi
- Topic: Timeline for MCD FDA submission
- Key points:
- Company just broadened access to MCD and started accessing clinical data (hundreds of thousands of patient data) to monitor clinical value, performance, and safety.
- Too early to put a specific timeline for FDA approval; will monitor and discuss at the right time.
- Mgmt stance: Neutral — optimistic about evidence-building potential but no commitment on timeline; waiting for more confidence.
Q5 — Patrick Donnelly
- Topic: Reveal test per patient traction and near-term catalysts
- Key points:
- Surveillance indication from a reimbursement point of view enabled pulling in subsequent test orders; systems now in place.
- Number of tests per patient has “gone up pretty nicely”; still in early cycles of capitalizing on that investment.
- Future catalysts include SERENA-6 (ESR1), therapy monitoring launch based on Reveal, and MRD/recurrence monitoring setting.
- Mgmt stance: Bullish — pleased with progress and return on investment; sees “great progress” and early-stage opportunity.
Q&A Batch (6-10 of 13)
Q6 — Tycho Peterson
- Topic: PEGASUS数据对MRD治疗管理的影响及临床效用证据与NCCN指南
- Key points:
- PEGASUS为Phase II信号寻找研究，可使约75%患者免于化疗，大幅降低神经毒性等不良反应
- 基于上一版Reveal；期待基于新版的TRACC研究
- ctDNA在辅助治疗和监测场景中可带来显著益处；持续投资Reveal平台的临床有效性和效用研究
- Mgmt stance: 乐观——PEGASUS提供良好基础，可通过更多数据和研究持续构建
Q7 — William Bonello
- Topic: Guardant360增长驱动因素及液体活检范式转变
- Key points:
- 液体活检渗透仍处于早期阶段；360在深度、灵敏度和应用场景上领先
- 并发检测（组织+液体）正成为标准，推动增长；预计成熟后每患者每年测试4.5次（当前1次/终身）
- 生物制药伙伴已在Phase I-III研究中使用监测测试
- Mgmt stance: 乐观——Guardant360和Reveal为真正平台，应用场景逐季/逐年增加，支撑投资者日指引轨迹
Q8 — Unknown Analyst
- Topic: Reveal与Ultra的研发投入及MRD市场增长展望
- Key points:
- Reveal为市场领先的无组织MRD检测；计划明年数据生成量达10倍
- MRD市场渗透率约10%；Reveal Ultra利用低输入量、快速周转和灵敏度优势
- 肿瘤知情端存在大量机会；Ultra预计将显著优于现有产品
- Mgmt stance: 乐观——MRD特许经营加速，Reveal Ultra技术整合公司全部能力，即将推出
Q9 — Mark Massaro
- Topic: Shield顺序增长指引及Reveal Ultra商业化与CMS报销时间
- Key points:
- Q4指引中点为环比增长8000例；Quest、PathGroup合作及指南纳入为催化剂
- Reveal Ultra灵敏度可达远低于当前水平的1ppm；商业推出时间保密但进展顺利
- 2028年目标保持不变；Q4后将讨论明年情况
- Mgmt stance: 乐观——催化剂众多，逐步推进2028年目标
Q10 — Casey Woodring
- Topic: Shield绩效KPI及Shield/Reveal毛利率
- Key points:
- Shield订单广度和深度环比提升； adherence rate高，多数订单转为样本
- Shield Q3毛利率55%，ISP约900美元，单测成本低于500美元
- Reveal ISP 600-700美元，单测成本低于500美元；整体毛利率从去年Q3的63%升至66%
- Mgmt stance: 乐观——Shield和Reveal毛利率均实现显著改善，推动整体毛利率提升
Q&A Batch (11-13 of 13)
Q11 — Kyle Mikson
- Topic: Reveal ADLT地位、乳腺Medicare覆盖及竞争对手AA敏感性数据
- Key points: ADLT仍为进行中工作，受政府关门影响；乳腺与IO覆盖更可能在明年年初；竞争对手AA敏感性下限15%，研究含大量小病灶；Shield AA为13%，公司有3年CRC领先优势
- Mgmt stance: 中性偏谨慎，因ADLT与覆盖时间表存在不确定性，但对技术栈与数据领导地位表示信心
Q12 — Luke Sergott
- Topic: OpEx阶梯式增长及S&M投入分配
- Key points: OpEx增量几乎全部用于销售与营销；筛查端已超250名销售代表；肿瘤端销售团队规模更大；2026年S&M将继续类似增长，R&D与G&A保持相对平稳
- Mgmt stance: 中性，强调将增量毛利再投资于商业化建设以支持规模化
Q13 — Daniel Brennan
- Topic: G360量指引及增长驱动因素
- Key points: 临床肿瘤量指引大于30% YoY，Q4延续Q3环比增长；G360增长主要来自其他医院份额获取；纵向检测增加占比很小；渗透未知原发癌等长尾癌种
- Mgmt stance: 乐观，因测试价值主张强，份额获取与长尾渗透提供持续动能